FTORPIRIMIDINY V KhIMIOTERAPII DISSEMINIROVANNOGO KOLOREKTAL'NOGO RAKA U BOL'NYKh POZhILOGO VOZRASTA


Cite item

Full Text

Abstract

Рассматриваются современные возможности химиотерапии метастатического колоректального рака с использованием фторпиримидинов - фторурацила и капецитабина (Кселоды). Обсуждаются особенности противоопухолевого лечения пожилых больных, при котором на первый план выходят проблемы безопасности. Приводятся данные об эффективности и безопасности у пациентов старших возрастных групп различных фторпиримидин-содержащих режимов химиотерапии, в т. ч. в сочетании с иринотеканом, оксалиплатином и бевацизумабом. Подчеркивается, что контролируемая и управляемая токсичность, высокая эффективность и возможность амбулаторного применения делают Кселоду идеальным препаратом для лечения пожилых больных.

Full Text

Restricted Access

About the authors

N. S Besova

References

  1. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-08.
  2. Thirion P, Michiels S, Pignon J.P, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an update metaanalysis. The Meta-analysis Group in Cancer. J Clin Oncol 2004;22:3766-75.
  3. Kohne C.H, Wils J, Lorens M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003;21:3721-28.
  4. De Gramont A, Bosset J.F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-15.
  5. Kohne C.H, Cunningham D, Di C.F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13:308-17.
  6. Yuste A.L, Aparicio J, Segura A, et al. Analysis of clinical prognostic factors for survival and time to Progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer. 2003;2:231-34.
  7. Comella P, Casaretti R, Sandomenico C, et al. Capecitabine, Alone and in combination in management of patients with colorectal cancer. Drugs 2008;68(7):949-61.
  8. Koukourakis G.V, Kouloulias V, Koukourakis M.J, et al. Efficacy of the oral Fluorouracil pro-drug Capecitabine in Cancer treatment: a review. Molecules 2008;13:1897-922.
  9. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.
  10. PrelBudman D.R, Meropol N.J, Reigner B, et al. Preliminary studies of novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 1998;16:1795-802.
  11. Osterwalder O, Rutman O. Final Clinical Study Report. Protocol NO15542B. A phase 2 study of capecitabine (Ro 09 1978) in patients who have received previous treatment with paclitaxel (Taxol™) or docetaxel (Taxotere™ ) for locally advanced and/or metastatic breast cancer. Longauer M. Brown T. Niederberger W. Neuckel W. Periodic Safety Update. Review period: November 1, 1998 - April 30, 1999. Research Report B-170974 July 12, 1999.
  12. DeVita V.T. Hellman S, Rosenberg S.A. Cancer, Principles and Practice of Oncology: Lippincott-Raven 1997;1:439-40.
  13. Anand A.J. Fluorouracil cardiotoxicity. Ann Pharmacother 1994;28:374-78.
  14. Meyer C.M, Calis K.A, Burke L.B, et al. Symptomatic cardiotoxicity associated with 5-FU. Pharmacotherapy 1997;17(4):729-36.
  15. Tuxen M.K, Hansen S.W. Neurotoxicity secondary to neoplastic drugs. Cancer Treatment Reviews 1994;20:191-214.
  16. Bygrave H.A, Geh J.I, Jani Y, et al. Neurological complications of 5-fluorouracil chemotherapy: case report and review of the literature. Clin Oncol 1998;10:334-36.
  17. Gilbert M.R. The neurotoxicity of cancer chemotherapy. The Neurologist 1998;4(2):43-53.
  18. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106.
  19. Hoff P.M, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
  20. Twelves C. Capecitabine as first-line treatment in colorectal cancer: pooled data from large phase III trials, Capecitabine Colorectal Cancer Group. Eur J Cancer 2002; 38(Suppl. 2):15-20.
  21. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Onc 2003;1(Suppl. 2):18-24.
  22. Balducci L, Exetrmann M. Management of cancer in older person: practical approach. Oncol 2000;5(3):224-37.
  23. Inoyue S.K, Peduzzi P.N, Robison J.T. et al. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998;279:1187-93.
  24. Reuben D.B, Rubenstein L.V, Hirsch S.H, et al. Value of functional status as predictor of mortality. Am J Med 1992;93:663-69.
  25. Siu A.L, Moshita L, Blaustein J. Comprehensive geriatric assessment in a day hospital. J Am Geriatr Soc 1994;42:1094-99.
  26. Satariano W.A, Ragland D.R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-10.
  27. Balducci L. The geriatric patient: equal benefit from equal treatment. Cancer Control 2001;8(2s):1-25.
  28. Wildiers H, Highley M.S, et al. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003;42(14):1213-42.
  29. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004;15:1330-38.
  30. Chiara S, Nobile M.T, Vincenti M, et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 1998;42:336-40.
  31. Jacobson S.D, Cha S, Sargent D.J, et al. Tolerabiliti, dose intensity, and benefit of 5-FU-based chemotherapy for advanced colorectal cancer (CRC) in the elderly. A North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 2001 ;20:A587.
  32. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colirectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leu-covorin. Ann Oncol 2002;13:566-75.
  33. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005;23:3104-11.
  34. Vincent M, Jonker D, Kerr I, et al. Reduced dose capecitabine as first-line therapy in older and less fit patients with advanced colorectal cancer. ASCO 2005. J Clin Oncol. Abstr.
  35. http://www.rocheuse.com/products/ XELODA/PI.pdf.
  36. Petrioli R, Pascucci A, Francini E, et al. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. Anti-Cancer Drugs 2008;19:91-96.
  37. Bollina R, Beretta G, Toniolo D, et al. Capecitabine and Irinotecan (CAPIRI): A good combination in the elderly hatients with advanced colorectal cancer as first-line chemotherapy. Preliminary results of a phase II trial. Pro Am Soc Clin Oncol 2006;24:3577.
  38. Barrueco J, Marshall J, Mitchell E. Safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in mCRC patients >65 years compared with those №65: the BICC-C study. J Clin Oncol 2007;25(18S):abstr. 4076.
  39. Folprecht G, Seymour M.T, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy for older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials, J Clin Oncol 2008;26:1443-51.
  40. Mitry E, Phelip J.M, Bonnetain F, et al. Phase III trial chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients. FFCD 2001-02 trial. Results of a planned interim analysis. Presented at: American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium; Jan 25-27, 2008, Orlando, FL. Abstr. 3524.
  41. Sastre J, Marcuello E, Massutti B, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005;23:3545-51.
  42. Souglakos J, Pallis A, Kakolyris S, et al. Combination of irinotecan plus 5-fluorouracil and leucovorin as first-line treatment for elderly patients with metastatic colorectal cancer: A phase II trial. Oncology 2005;69:384-90.
  43. Cassidy J, Tabernero J, Twelves C, et al. Capecitabine plus oxaliplatin first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-91.
  44. Goldberg R.M, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-91.
  45. Hockster H.S, Luo W, Popa E.C, et al. Phase II study of uracil-tegafur with leucovarin in elderly (≥ 75 years old) patients with colorectal cancer: ECOG 1299. J Clin Oncol 2007; 25:5397-402.
  46. Figer A, Perez-Staub N, Carola E, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007;110:2666-71.
  47. Berretta M, Bearz A, Frustaci S, et al. FOLFOX2 regimen in the treatment of advanced colorectal cancer: comparison between elderly and young patients. Ann Oncol 2006; 17:1606-07.
  48. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Itali Cooperative Oncology Group trial 0108. Cancer 2005;104:289-99.
  49. Kozloff M, Sugrue M, Berlin J, et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients with metastatic colorectal cancer (mCRC): results from the BRITE observational Cohort Study. J Clin Oncol 2008;26(Suppl.):abs 4026.
  50. Puthillath A.A, Mashtare T, Wilding G, et al. A phase II study of first-line biweekly regiment of capecitabine (CAP) and bevacizumab (BV) in elderly patients with metastatic colorectal cancer. Presented at: 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; Jan 25-27, 2008, Orlando, FL. Abstr. 511.
  51. Feliu J, Salut A, Losa F, et al. Bevacizumab plus capecitabine as first-line therapy for advanced or metastatic colorectal cancer in elderly patients. Intermediate results. oncopaz cooperative group study. Presented at: 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; Jan 25-27, 2008, Orlando, FL. Abstr. 479.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies